[go: up one dir, main page]

MX2010010235A - Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors. - Google Patents

Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors.

Info

Publication number
MX2010010235A
MX2010010235A MX2010010235A MX2010010235A MX2010010235A MX 2010010235 A MX2010010235 A MX 2010010235A MX 2010010235 A MX2010010235 A MX 2010010235A MX 2010010235 A MX2010010235 A MX 2010010235A MX 2010010235 A MX2010010235 A MX 2010010235A
Authority
MX
Mexico
Prior art keywords
indolobenzadiazepine
hcv ns5b
ns5b inhibitors
pyrrolidine fused
pyrrolidine
Prior art date
Application number
MX2010010235A
Other languages
Spanish (es)
Inventor
John F Kadow
John A Bender
Zhong Yang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2010010235A publication Critical patent/MX2010010235A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
MX2010010235A 2008-03-27 2009-03-25 Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors. MX2010010235A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3997308P 2008-03-27 2008-03-27
PCT/US2009/038167 WO2009120733A1 (en) 2008-03-27 2009-03-25 Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors

Publications (1)

Publication Number Publication Date
MX2010010235A true MX2010010235A (en) 2010-10-05

Family

ID=40791440

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010010235A MX2010010235A (en) 2008-03-27 2009-03-25 Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors.

Country Status (8)

Country Link
US (1) US8119628B2 (en)
EP (1) EP2280978B1 (en)
JP (1) JP2011515484A (en)
KR (1) KR20100126560A (en)
CN (1) CN102046630A (en)
ES (1) ES2416062T3 (en)
MX (1) MX2010010235A (en)
WO (1) WO2009120733A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011515486A (en) 2008-03-27 2011-05-19 ブリストル−マイヤーズ スクイブ カンパニー Compound for the treatment of hepatitis C
CN105481864A (en) 2009-05-22 2016-04-13 Abbvie公司 Modulators of 5-HT receptors and methods of use thereof
KR101799272B1 (en) 2010-02-03 2017-11-20 엘지전자 주식회사 Apparatus and method of transmitting control information in wireless communication system
WO2011146089A1 (en) 2010-05-21 2011-11-24 Abbott Laboratories Modulators of 5-ht receptors and methods of use thereof
CN102924462B (en) * 2012-10-24 2015-01-14 华东师范大学 Method for synthesis of 1,2,3,4,5,9-substituted benzazepine compound

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005013922D1 (en) 2004-02-24 2009-05-28 Japan Tobacco Inc CONDENSED HETEROTETRACYCLIC COMPOUNDS AND THEIR USE AS HCV POLYMERASE INHIBITOR
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
PE20060607A1 (en) 2004-10-26 2006-07-14 Angeletti P Ist Richerche Bio TETRACYCLIC INDEOL DERIVATIVES AS ANTIVIRAL AGENTS
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) * 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521443B2 (en) 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
ES2343914T3 (en) 2006-05-25 2010-08-12 Bristol-Myers Squibb Company INDOLOBENZAZEPIN HCV NS5B INHIBITORS CONDENSED WITH CYCLOPROPYL.
US7521442B2 (en) 2006-05-25 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7452876B2 (en) 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7541351B2 (en) 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7998951B2 (en) 2007-03-05 2011-08-16 Bristol-Myers Squibb Company HCV NS5B inhibitors
US7541353B2 (en) 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7521444B2 (en) 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7547690B2 (en) 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7538102B2 (en) 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7538103B2 (en) 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US20090018163A1 (en) 2007-07-11 2009-01-15 Bristol-Myers Squibb Company Substituted Heterocyclic Ethers and Their Use in CNS Disorders
PT2209789E (en) 2007-11-20 2012-01-16 Bristol Myers Squibb Co Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US8129367B2 (en) 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8124601B2 (en) 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
JP2011515486A (en) 2008-03-27 2011-05-19 ブリストル−マイヤーズ スクイブ カンパニー Compound for the treatment of hepatitis C
US8143244B2 (en) 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors

Also Published As

Publication number Publication date
JP2011515484A (en) 2011-05-19
CN102046630A (en) 2011-05-04
US8119628B2 (en) 2012-02-21
EP2280978B1 (en) 2013-04-24
AU2009228325A1 (en) 2009-10-01
WO2009120733A1 (en) 2009-10-01
ES2416062T3 (en) 2013-07-30
KR20100126560A (en) 2010-12-01
US20110020276A1 (en) 2011-01-27
EP2280978A1 (en) 2011-02-09

Similar Documents

Publication Publication Date Title
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
MX2012004032A (en) Compounds for the treatment of hepatitis c.
PL1987038T3 (en) Hcv ns5b inhibitors
WO2010030538A3 (en) Compounds for the treatment of hepatitis c
ATE469155T1 (en) CYCLOPROPYL-FUSIONED INDOLEBENZAZEPINE HCV NS5B INHIBITORS
SI2209789T1 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
MX2009009473A (en) Compounds for the treatment of hepatitis c.
EA201100390A1 (en) CONNECTIONS FOR THE TREATMENT OF HEPATITIS C
TW200745035A (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
MX2010008699A (en) Heterocyclic derivatives as hepatitis c virus inhibitors.
MX2010008531A (en) Conformationally restricted biphenyl derivatives for use as hepatitis c virus inhibitors.
MX2010008749A (en) Hepatitis c virus inhibitors.
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
WO2007140200A3 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
MX2009004888A (en) Hepatitis c virus inhibitors.
EA200900297A1 (en) HEPATITIS C VIRUS INHIBITORS
MX337050B (en) 4 ' - azido - nucleosides as anti - hcv compunds.
CO6190510A2 (en) HEPATITIS C VIRUS INHIBITORS
MX2013002927A (en) Hepatitis c virus inhibitors.
ATE522532T1 (en) COMPOUNDS FOR TREATING HEPATITIS C
MX2010001416A (en) Compounds for the treatment of hepatitis c.
ATE494291T1 (en) COMPOUNDS FOR TREATING HEPATITIS C
ATE551343T1 (en) TETRACYCLIC COMPOUNDS FOR THE TREATMENT OF HEPATITIS C
ATE505473T1 (en) CYCLOPROPYL-CONDENSED INDOLOBENZAZEPINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C
MX2010010061A (en) Compounds for the treatment of hepatitis c.

Legal Events

Date Code Title Description
FG Grant or registration